Lipocine Inc. (LPCN)
Stock Price:
$1.71 USD
0.17 (11.04%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $1.69 -0.02 (-1.17%) Aug 3, 4:25 PM
Key Info
| Market Cap |
81.87M |
| Revenue (ttm) |
164,990 |
| Net Income (ttm) |
-15.55M |
| Shares Out |
47.88M |
| EPS (ttm) |
-0.51 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$1.71 |
| Previous Close |
$1.54 |
| Change ($) |
0.17 |
| Change (%) |
11.04% |
| Day's Open |
1.69 |
| Day's Range |
1.57 - 1.84 |
| Day's Volume |
11,436,460 |
| 52-Week Range |
0.30 - 3.45 |
More Stats
| Market Cap |
81.87M |
| Enterprise Value |
67.65M |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
47.88M |
| Float |
46.11M |
| EPS (basic) |
-0.5 |
| EPS (diluted) |
-0.51 |
| FCF / Share |
-0.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.02M |
| Short Ratio |
0.35 |
| Short % of Float |
1.72% |
| Beta |
0.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
496.24 |
| PB Ratio |
10.96 |
| Revenue |
164,990 |
| Operating Income |
-14.37M |
| Net Income |
-15.55M |
| Free Cash Flow |
-12.04M |
| Net Cash |
14.23M |
| Net Cash / Share |
0.30 |
| Gross Margin |
-3,063.03% |
| Operating Margin |
-8,710.87% |
| Profit Margin |
-9,426.90% |
| FCF Margin |
-7,297.17% |
| ROA |
-40.85% |
| ROE |
-162.83% |
| ROIC |
-184.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.00*
(75.44% upside)
Low
3.00
Current: $1.71
High
3.00
Target: 3.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 0.16 | 0.43 | - | - | - | - | - | 7.71 | - |
| Revenue Growth | -61.45% | - | - | - | - | - | - | - | - |
| Gross Profit | 0.16 | 0.43 | - | - | - | - | - | 7.71 | - |
| Operating Income | -12.90 | -11.33 | -21.22 | -19.19 | -18.38 | -20.48 | -10.68 | 3.88 | -0.01 |
| Net Income | -13.01 | -11.66 | -20.98 | -18.97 | -18.21 | -20.37 | -10.59 | 3.89 | -0.01 |
| Shares Outstanding | 25.88 | 21.35 | 20.05 | 18.26 | 16.47 | 12.77 | 7.36 | 4.46 | 1.80 |
| Earnings Per Share | -0.50 | -0.55 | -1.05 | -1.04 | -1.11 | -1.60 | -1.44 | 0.85 | - |
| Operating Cash Flow | -11.67 | -12.08 | -16.70 | -18.28 | -15.36 | -17.30 | -8.59 | -3.18 | -0.01 |
| Capital Expenditures | - | - | - | -0.06 | -0.03 | -0.06 | - | -0.01 | - |
| Free Cash Flow | -11.67 | -12.08 | -16.70 | -18.34 | -15.38 | -17.36 | -8.59 | -3.19 | -0.01 |
| Cash & Equivalents | 19.07 | 20.25 | 21.47 | 26.84 | 44.38 | 27.67 | 45.26 | 5.38 | 0.02 |
| Total Debt | 7.15 | 10.26 | - | - | - | - | - | - | - |
| Net Cash / Debt | 11.92 | 9.99 | 21.47 | 26.84 | 44.38 | 27.67 | 45.26 | 5.38 | 0.02 |
| Assets | 19.66 | 20.85 | 25.33 | 27.34 | 45.38 | 27.99 | 46.11 | 5.57 | 0.03 |
| Liabilities | 13.37 | 11.42 | 6.35 | 1.33 | 3.39 | 1.63 | 1.28 | 0.25 | 0.01 |
| Book Value | 6.29 | 9.43 | 18.98 | 26.02 | 41.99 | 26.36 | 44.82 | 5.32 | 0.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Lipocine Inc. |
| Country |
United States |
| Employees |
12 |
| CEO |
Mahesh V. Patel |
Stock Information
| Ticker Symbol |
LPCN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LPCN |
Description
Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.